Close Menu

NEW YORK – Investment bank Piper Jaffray today upgraded shares of Pacific Biosciences to Overweight after conducting checks on placements of the firm's Sequel II single-molecule sequencing instrument.

Piper Jaffray analyst William Quirk wrote in a note to investors that the bank's channel checks imply 36 to 42 placements of the Sequel II, which launched earlier this year, in the third quarter. He noted that PacBio had placed 41 Sequel II instruments through the second quarter of 2019, which was above his expectations of around 25.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).

Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.